ATRC:NSD-AtriCure Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 72.59

Change

-4.12 (-5.37)%

Market Cap

USD 3.33B

Volume

0.16M

Avg Analyst Target

USD 89.08 (+22.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio. Address: 7555 Innovation Way, Mason, OH, United States, 45040

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

-23.28 (-2.24%)

USD123.43B 77.45 62.08
HOLX Hologic Inc

-0.90 (-1.16%)

USD19.68B 9.95 7.22
RGEN Repligen Corporation

-0.85 (-0.28%)

USD16.87B 170.59 106.78
MASI Masimo Corporation

-1.34 (-0.49%)

USD15.11B 71.08 50.02
NVCR NovoCure Limited

-3.83 (-2.92%)

USD13.58B 1,480.87 528.28
XRAY DENTSPLY SIRONA Inc

-1.58 (-2.58%)

USD13.38B 36.53 17.47
STAA STAAR Surgical Company

-3.31 (-2.31%)

USD6.80B 351.40 218.19
ICUI ICU Medical Inc

-1.59 (-0.66%)

USD5.10B 50.50 21.60
MMSI Merit Medical Systems Inc

-0.08 (-0.11%)

USD4.03B 143.30 31.03
NSTG NanoString Technologies Inc

-2.76 (-4.78%)

USD2.63B N/A N/A

ETFs Containing ATRC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.39% 77% C+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.39% 77% C+ 78% C+
Trailing 12 Months  
Capital Gain 87.81% 83% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.81% 83% B 80% B-
Trailing 5 Years  
Capital Gain 354.82% 77% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 354.82% 77% C+ 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 36.75% 63% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.75% 63% D 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 32.85% 77% C+ 56% F
Risk Adjusted Return 111.86% 83% B 95% A
Market Capitalization 3.33B 73% C 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.14 27% F 16% F
Price / Cash Flow Ratio -167.63 94% A 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -14.14% 36% F 42% F
Return on Invested Capital -11.32% 27% F 33% F
Return on Assets -3.25% 38% F 37% F
Debt to Equity Ratio 12.96% 63% D 68% D+
Technical Ratios  
Short Ratio 3.28 64% D 51% F
Short Percent 2.03% 70% C- 59% F
Beta 1.04 65% D 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector